ZERBAXA®

(ceftolozane and tazobactam) for injection (1.5 g), for intravenous use

Announcements

Announcements

  • ZERBAXA Is Indicated for the Treatment of Pediatric Patients (Birth to Less Than 18 Years Old) with cUTI or cIAI. See Prescribing Information for details.

Safety - Adverse Reactions

Learn about:

Clinical trials experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and also may not reflect rates observed in practice.

Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)

ZERBAXA was evaluated in a Phase 3 comparator-controlled clinical trial for HABP/VABP, which included a total of 361 patients treated with ZERBAXA (3 g every 8 hours, adjusted based on renal function where appropriate) and 359 patients treated with comparator (meropenem 1 g every 8 hours) for up to 14 days. The mean age of treated patients was 60 years (range 18 to 98 years), across treatment arms. About 44% of the subjects were 65 years of age or older. Most patients (71%) enrolled in the trial were male. All subjects were mechanically ventilated at randomization and 92% were in an intensive care unit (ICU) at randomization. The median APACHE II score was 17, and 33% of subjects had a baseline APACHE II score of ≥20, indicating a high severity of illness for many patients enrolled in this trial.

The table below lists adverse reactions occurring in 2% or greater of patients receiving ZERBAXA in a Phase 3 HABP/VABP clinical trial.

Adverse reactions occurring in 2% or greater of adult patients receiving ZERBAXA in a Phase 3 HABP/VABP clinical trial

Adverse reactions
ZERBAXAaN=361 n (%) Meropenem N=359 n (%)
Hepatic transaminase increasedb 43 (11.9) 26 (7.2)
Renal impairment/renal failurec 32 (8.9) 22 (6.1)
Diarrhea 23 (6.4) 25 (7.0)
Intracranial hemorrhaged 16 (4.4) 5 (1.4)
Vomiting 12 (3.3) 10 (2.8)
Clostridioides difficile colitise 10 (2.8) 2 (0.6)
  • aThe ZERBAXA for injection dose was 3 g intravenously every 8 hours, adjusted to match renal function where appropriate.
  • bIncludes alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzyme increased, hypertransaminasaemia, liver function test abnormal.
  • cIncludes acute renal failure, anuria, azotemia, oliguria, prerenal failure, renal failure, renal impairment.
  • dIncludes cerebellar hemorrhage, cerebral hematoma, cerebral hemorrhage, hemorrhage intracranial, hemorrhagic stroke, hemorrhagic transformation stroke, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma.
  • eIncludes Clostridioides difficile colitis, Clostridioides difficile infection, Clostridioides test positive.
Treatment discontinuation due to adverse reactions occurred in 1.1% (4/361) of patients receiving ZERBAXA and 1.4% (5/359) of patients receiving meropenem.

Less common adverse reactions in a Phase 3 HABP/VABP clinical trial

The following selected adverse reactions were reported in ZERBAXA-treated subjects at a rate of less than 2%:
  • Investigations: blood alkaline phosphatase increased, gamma-glutamyltransferase increased, Coombs direct test positive

Complicated intra-abdominal infections and complicated urinary tract infections for adult patients, including pyelonephritis

ZERBAXA was evaluated in Phase 3 comparator-controlled clinical trials of cIAI and cUTI, which included a total of 1015 patients treated with ZERBAXA (1.5 g every 8 hours, adjusted based on renal function where appropriate) and 1032 patients treated with comparator (levofloxacin 750 mg daily in cUTI or meropenem 1 g every 8 hours in cIAI) for up to 14 days. The mean age of treated patients was 48 to 50 years (range 18 to 92 years), across treatment arms and indications. In both indications, about 25% of the subjects were 65 years of age or older. Most patients (75%) enrolled in the cUTI trial were female, and most patients (58%) enrolled in the cIAI trial were male. Most patients (>70%) in both trials were enrolled in Eastern Europe and were White.

The most common adverse reactions (5% or greater in either indication) occurring in patients receiving ZERBAXA were nausea, diarrhea, headache, and pyrexia. The table below lists adverse reactions occurring in 1% or greater of patients receiving ZERBAXA in Phase 3 cIAI and cUTI clinical trials.

Adverse reactions occurring in 1% or greater of adult patients (18 years and older) receiving ZERBAXA in Phase 3 cIAI and cUTI clinical trials

For Nausea: ZERBAXA in cIAI is 38 (7.9), Meropenem in cIAI is 29 (5.8), ZERBAXA in cUTI is 15 (2.8), Meropenem in cUTI is 9 (1.7). For Headache: ZERBAXA in cIAI is 12 (2.5), Meropenem in cIAI is 9 (1.8), ZERBAXA in cUTI is 31 (5.8), Meropenem in cUTI is 26 (4.9). For Diarrhea: ZERBAXA in cIAI is 30 (6.2), Meropenem in cIAI is 25 (5), ZERBAXA in cUTI is 10 (1.9), Meropenem in cUTI is 23 (4.3). For Pyrexia: ZERBAXA in cIAI is 27 (5.6), Meropenem in cIAI is 20 (4), ZERBAXA in cUTI is 9 (1.7), Meropenem in cUTI is 5 (0.9). For Constipation: ZERBAXA in cIAI is 9 (1.9), Meropenem in cIAI is 6 (1.2), ZERBAXA in cUTI is 21 (3.9), Meropenem in cUTI is 17 (3.2). For Insomnia: ZERBAXA in cIAI is 17 (3.5), Meropenem in cIAI is 11 (2.2), ZERBAXA in cUTI is 7 (1.3), Meropenem in cUTI is 14 (2.6). For Vomiting: ZERBAXA in cIAI is 16 (3.3), Meropenem in cIAI is 20 (4), ZERBAXA in cUTI is 6 (1.1), Meropenem in cUTI is 6 (1.1). For Hypokalemia: ZERBAXA in cIAI is 16 (3.3), Meropenem in cIAI is 10 (2), ZERBAXA in cUTI is 4 (0.8), Meropenem in cUTI is 2 (0.4). For ALT increased: ZERBAXA in cIAI is 7 (1.5), Meropenem in cIAI is 5 (1), ZERBAXA in cUTI is 9 (1.7), Meropenem in cUTI is 5 (0.9). For AST increased: ZERBAXA in cIAI is 5 (1), Meropenem in cIAI is 3 (0.6), ZERBAXA in cUTI is 9 (1.7), Meropenem in cUTI is 5 (0.9). For Anemia: ZERBAXA in cIAI is 7 (1.5), Meropenem in cIAI is 5 (1), ZERBAXA in cUTI is 2 (0.4), Meropenem in cUTI is 5 (0.9). For Thrombocytosis: ZERBAXA in cIAI is 9 (1.9), Meropenem in cIAI is 5 (1), ZERBAXA in cUTI is 2 (0.4), Meropenem in cUTI is 2 (0.4). For Abdominal pain: ZERBAXA in cIAI is 6 (1.2), Meropenem in cIAI is 2 (0.4), ZERBAXA in cUTI is 4 (0.8), Meropenem in cUTI is 2 (0.4). For Anxiety: ZERBAXA in cIAI is 9 (1.9), Meropenem in cIAI is 7 (1.4), ZERBAXA in cUTI is 1 (0.2), Meropenem in cUTI is 4 (0.7). For Dizziness: ZERBAXA in cIAI is 4 (0.8), Meropenem in cIAI is 5 (1), ZERBAXA in cUTI is 6 (1.1), Meropenem in cUTI is 1 (0.2). For Hypotension: ZERBAXA in cIAI is 8 (1.7), Meropenem in cIAI is 4 (0.8), ZERBAXA in cUTI is 2 (0.4), Meropenem in cUTI is 1 (0.2). For Atrial fibrillation: ZERBAXA in cIAI is 6 (1.2), Meropenem in cIAI is 3 (0.6), ZERBAXA in cUTI is 1 (0.2), Meropenem in cUTI is 0. For Rash: ZERBAXA in cIAI is 8 (1.7), Meropenem in cIAI is 7 (1.4), ZERBAXA in cUTI is 5 (0.9), Meropenem in cUTI is 2 (0.4). Preferred term Complicated intra- abdominal infections Complicated urinary tract infections, including pyelonephritis ZERBAXA a (N=482) n (%) Meropenem Levofloxacin (N=497) n (%) ZERBAXA a (N=482) n (%) (N=535) n (%) Nausea 38 (7.9) 29 (5.8) 15 (2.8) 9 (1.7) Headache 12 (2.5) 9 (1.8) 31 (5.8) 26 (4.9) Diarrhea 30 (6.2) 25 (5) 10 (1.9) 23 (4.3) Pyrexia 27 (5.6) 20 (4) 9 (1.7) 5 (0.9) Constipation 9 (1.9) 6 (1.2) 21 (3.9) 17 (3.2) Insomnia 17 (3.5) 11 (2.2) 7 (1.3) 14 (2.6) Vomiting 16 (3.3) 20 (4) 6 (1.1) 6 (1.1) Hypokalemia 16 (3.3) 10 (2) 4 (0.8) 2 (0.4) ALT increased 7 (1.5) 5 (1) 9 (1.7) 5 (0.9) AST increased 5 (1) 3 (0.6) 9 (1.7) 5 (0.9) Anemia 7 (1.5) 5 (1) 2 (0.4) 5 (0.9) Thrombocytosis 9 (1.9) 5 (1) 2 (0.4) 2 (0.4) Abdominal pain 6 (1.2) 2 (0.4) 4 (0.8) 2 (0.4) Anxiety 9 (1.9) 7 (1.4) 1 (0.2) 4 (0.7) Dizziness 4 (0.8) 5 (1) 6 (1.1) 1 (0.2) Hypotension Atrial fibrillation 8 (1.7) 4 (0.8) 2 (0.4) 1 (0.2) 6 (1.2) 3 (0.6) 1 (0.2) 0 Rash 8 (1.7) 7 (1.4) 5 (0.9) 2 (0.4)

aThe ZERBAXA for injection dose was 1.5 g intravenously every 8 hours, adjusted to match renal function where appropriate. In the cIAI trials, ZERBAXA was given in conjunction with metronidazole.

Treatment discontinuation due to adverse events occurred in 2.0% (20/1015) of patients receiving ZERBAXA and 1.9% (20/1032) of patients receiving comparator drugs. Renal impairment (including the terms renal impairment, renal failure, and renal failure acute) led to discontinuation of treatment in 5/1015 (0.5%) subjects receiving ZERBAXA and none in the comparator arms.

Increased mortality

In the cIAI trials (Phase 2 and 3), death occurred in 2.5% (14/564) of patients receiving ZERBAXA and in 1.5% (8/536) of patients receiving meropenem. The causes of death varied and included worsening and/or complications of infection, surgery and underlying conditions.

Less common adverse reactions in Phase 3 cIAI and cUTI clinical trials

The following selected adverse reactions were reported in ZERBAXA-treated subjects at a rate of less than 1%:
  • Cardiac disorders: tachycardia, angina pectoris
  • Gastrointestinal disorders: gastritis, abdominal distension, dyspepsia, flatulence, ileus paralytic
  • General disorders and administration site conditions: infusion site reactions
  • Infections and infestations: candidiasis including oropharyngeal and vulvovaginal, fungal urinary tract infection
  • Investigations: increased serum gamma-glutamyl transpeptidase (GGT), increased serum alkaline phosphatase, positive Coombs test
  • Metabolism and nutrition disorders: hyperglycemia, hypomagnesemia, hypophosphatemia
  • Nervous system disorders: ischemic stroke
  • Renal and urinary system: renal impairment, renal failure
  • Respiratory, thoracic and mediastinal disorders: dyspnea
  • Skin and subcutaneous tissue disorders: urticaria
  • Vascular disorders: venous thrombosis

Complicated intra-abdominal infections and complicated urinary tract infections for pediatric patients, including pyelonephritis

ZERBAXA was evaluated in two blinded, randomized, active-controlled clinical studies in pediatric patients from birth to less than 18 years of age, one in cIAI and the other in cUTI, which included a total of 170 pediatric patients treated with ZERBAXA and 54 pediatric patients treated with the comparator. The ZERBAXA dosing regimen was the same in each trial. Patients were randomized 3:1 to receive ZERBAXA plus metronidazole or meropenem plus placebo in the cIAI study and ZERBAXA or meropenem in the cUTI study. In these pediatric patients, the type of adverse reactions were generally comparable to those observed in adults.

Adverse reactions occurring in 4% or greater of pediatric patients (birth to less than 18 years of age) receiving ZERBAXA in either the cIAI or cUTI clinical trial

Adverse Reaction Complicated intra-abdominal infections Complicated urinary tract infections, including pyelonephritis
ZERBAXAa
(N=70)
n (%)		 Meropenem
(N=21)
n (%)		 ZERBAXAa
(N=100)
n (%)		 Meropenem
(N=33)
n (%)
Thrombocytosisb 11 (16) 3 (14) 9 (9) 3 (9)
Diarrhea 12 (17) 5 (24) 7 (7) 3 (9)
Pyrexiac 9 (13) 3 (14) 7 (7) 1 (3)
Leukopeniad 3 (4) 0 (0) 8 (8) 0 (0)
Abdominal paine 8 (11) 0 (0) 2 (2) 1 (3)
AST increased 5 (7) 1 (5) 4 (4) 2 (6)
Vomiting 7 (10) 1 (5) 1 (1) 1 (3)
ALT increased 4 (6) 1 (5) 4 (4) 2 (6)
Anemia 5 (7) 0 (0) 2 (2) 0 (0)
Phlebitisf 4 (6) 0 (0) 1 (1) 1 (3)
Hypertension 3 (4) 0 (0) 0 (0) 1 (3)
Gastritis 3 (4) 0 (0) 0 (0) 0 (0)
Hypokalemiag 3 (4) 0 (0) 0 (0) 0 (0)
Bradypneah 3 (4) 0 (0) 0 (0) 0 (0)

aIn the cIAI trials, ZERBAXA was given in conjunction with metronidazole.

bIncludes platelet count increased.

cIncludes hyperthermia.

dIncludes neutropenia and neutrophil count decreased.

eIncludes upper abdominal pain.

fIncludes superficial phlebitis.

gIncludes blood potassium decreased.

hIncludes respiratory rate decreased.

Laboratory values

The development of a positive direct Coombs test may occur during treatment with ZERBAXA. The incidence of seroconversion to a positive direct Coombs test was 0.2% in patients receiving ZERBAXA and 0% in patients receiving the comparator in the adult cUTI and cIAI clinical trials. The incidence of seroconversion to a positive direct Coombs test was 31.2% in patients receiving ZERBAXA and 3.6% in patients receiving meropenem in the adult HABP/VABP clinical trial. The incidence of seroconversion to a positive direct Coombs test was 45.3% in patients receiving ZERBAXA and 33.3% in patients receiving meropenem in the pediatric cIAI clinical trial. The incidence of seroconversion to a positive direct Coombs test was 29.7% in patients receiving ZERBAXA and 8.7% in patients receiving meropenem in the pediatric cUTI clinical trial. In clinical trials, there was no evidence of hemolysis in patients who developed a positive direct Coombs test in any treatment group.

Indications and Usage

ZERBAXA is indicated for the treatment of adult patients (18 years and older) with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible Gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Serratia marcescens.

ZERBAXA is indicated for the treatment of adult and pediatric patients (birth to less than 18 years old) with complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa.

ZERBAXA used in combination with metronidazole is indicated for the treatment of adult and pediatric patients (birth to less than 18 years old) with complicated intra-abdominal infections (cIAI) caused by the following susceptible Gram-negative and Gram-positive microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, and Streptococcus salivarius.

Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Important Safety Information

  • Patients with renal impairment: Decreased efficacy of ZERBAXA has been observed in patients with baseline CrCl of 30 to ≤50 mL/min. In a clinical trial of adult patients, patients with cIAIs with CrCl >50 mL/min had a clinical cure rate of 85.2% when treated with ZERBAXA plus metronidazole vs 87.9% when treated with meropenem. In the same trial, patients with CrCl 30 to ≤50 mL/min had a clinical cure rate of 47.8% when treated with ZERBAXA plus metronidazole vs 69.2% when treated with meropenem. A similar trend was also seen in the cUTI trial. Dose adjustment is required for adult patients with CrCl 50 mL/min or less. All doses of ZERBAXA are administered over 1 hour. Monitor CrCl at least daily in patients with changing renal function and adjust the dose of ZERBAXA accordingly.
  • Hypersensitivity: ZERBAXA is contraindicated in patients with known serious hypersensitivity to the components of ZERBAXA (ceftolozane/ tazobactam), piperacillin/tazobactam, or other members of the beta-lactam class. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterials. Before initiating therapy with ZERBAXA, make careful inquiry about previous hypersensitivity reactions to cephalosporins, penicillins, or other beta-lactams. If an anaphylactic reaction to ZERBAXA occurs, discontinue use and institute appropriate therapy.
  • Clostridioides difficile-associated diarrhea (CDAD), ranging from mild diarrhea to fatal colitis, has been reported with nearly all systemic antibacterial agents, including ZERBAXA. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents. If CDAD is confirmed, antibacterial use not directed against C. difficile should be discontinued, if possible.
  • Development of drug-resistant bacteria: Prescribing ZERBAXA in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and risks the development of drug-resistant bacteria.
  • Adverse reactions in adult patients with HABP/VABP: The most common adverse reactions occurring in ≥5% of adult patients receiving ZERBAXA in the HABP/VABP trial were hepatic transaminase increased (11.9%), renal impairment/renal failure (8.9%), and diarrhea (6.4%).
  • Adverse reactions in adult patients with cIAI or cUTI: The most common adverse reactions occurring in ≥5% of adult patients receiving ZERBAXA in the cUTI and cIAI trials were headache (5.8%) in the cUTI trial, and nausea (7.9%), diarrhea (6.2%), and pyrexia (5.6%) in the cIAI trial.
  • Adverse reactions in pediatric patients with cIAI or cUTI: The most common adverse reactions occurring in ≥7% of pediatric patients receiving ZERBAXA in the cIAI trial were diarrhea (17%), thrombocytosis (16%), pyrexia (13%), abdominal pain (11%), vomiting (10%), increased aspartate aminotransferase (7%), and anemia (7%). The most common adverse reactions occurring in ≥7% of pediatric patients receiving ZERBAXA in the cUTI trial were thrombocytosis (9%), leukopenia (8%), diarrhea (7%), and pyrexia (7%).
  • Pediatric Use: There is insufficient information to recommend dosage adjustment for pediatric patients younger than 18 years of age with cIAI and cUTI with eGFR 50 mL/min/1.73m2 or less. ZERBAXA is not recommended in pediatric patients who have an eGFR 50 mL/min/1.73m2 or less. Pediatric patients born at term or pre-term may not have an eGFR of 50 mL/min/1.73m2 or greater at birth or within the first few months of life.

Before prescribing ZERBAXA, please read the accompanying Prescribing Information.

US-ZER-0146708/22